Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Edoardo Melilli
- Target Recruit Count
- 20
- Registration Number
- NCT03415750
- Locations
- 🇪🇸
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT03413722
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 211
- Registration Number
- NCT03386539
- Locations
- 🇺🇸
UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta Emory, Atlanta, Georgia, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Pediatric Brain Tumor Consortium
- Target Recruit Count
- 22
- Registration Number
- NCT03387020
- Locations
- 🇺🇸
National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸St. Jude Children Research Hospital, Memphis, Tennessee, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 19
- Registration Number
- NCT03355794
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
- Conditions
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03352427
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT03328104
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Yousef Zakharia
- Target Recruit Count
- 11
- Registration Number
- NCT03324373
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT03312738
- Locations
- 🇨🇳
Novartis Investigative Site, Wuhan, China
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Greater Baltimore Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT03285802
- Locations
- 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.